Havana, JUl 29 (Prensa Latina) Malaysian biotechnology firm BIOVEN, which is making clinical experiments Phase III on a promising vaccine against cancer made in Cuba, wants to create and finance a quoting office in London after a fruitful collaboration with Cuba.
The Cuban relation with BIOVEN, of which the Malaysian government is one of its greatest stockholders, is an example of the South-South colaboration, said Eltnard Blanco, comemrcial manager for Cuban commercializing enterprise CIMAB, which belongs to the Molecular Immunology of Cuba (CIM) of Cuba, which created the Cuban vaccine.

Since 2008, through an agreement with the CIM, Bioven makes the clinical development of the Cuban vaccine in Europe and parts of Asia and Oceania, said Blanco.

Since Bioven placed the drug -which targets cancer cells non-small lung in a larger post-test, and Stephen Drew, chief executive, said that from the Alternative Investment Market, the junior market of London Stock Exchange can help speed up the commercial thrust.

The drug is a kind of immunotherapy that targets proteins called EGF (epidermal growth factor) overexpressing cancer cells.

Phase III testing -Last before sought the approval regulatoria- began in May with the participation of 419 patients 10 countries.

Much of clinical development work is done in Scotland, in collaboration with the Cancer Beatson Institute in Glasgow.